Dylan Essner on Documentation Tools for CAR T-Cell Therapy

News
Article

Dylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.

Dylan Essner, an Epic Beacon Analyst at Washington University in St. Louis, talked about his work in implementing new documentation tools to streamline data for patients.

Transcription:

Within the CAR T(-cell) build in Epic, I helped mainly with the documentation tools for flow sheets. We have the CRS, ICANS and the ICE flow sheets, and I built all 3 of those flow sheets and included them in 1 flow sheet template that way the providers and nurses can go in and document their ICE, ICANS and CRS documentation. And then some of those--the ICANS and the ICE--have a formula built into the flow sheets that allows it to auto-populate the grade and score of the actual documentation. They just put in the different data points for each flow sheet and then we have a row at the bottom that auto-calculates the grade for each patient, so they don’t have to go in and do that.

And then for CRS they actually have to go in and we give them an informational chart they can look at, and then from there they can grade the patient from the bottom row. With that flow sheet data, we also built some smart links that pull the data from those flow sheets into the progress notes, so it automatically just populates into their progress notes making documentation for them a lot easier.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content